Mycophenolate mofetil: long-term outcomes in solid organ transplantation

Area of Science:

• Immunology
• Pharmacology
• Transplantation Medicine

Background:

• Mycophenolate mofetil (MMF) is the most utilized antiproliferative immunosuppressant in solid organ transplantation.
• MMF is the morpholinoethyl ester of mycophenolic acid (MPA), functioning as an inosine monophosphate dehydrogenase (IMPDH) inhibitor.

Purpose of the Study:

• To review the pharmacology of MMF.
• To summarize prospective clinical studies and long-term outcomes data for MMF in kidney and liver transplantation.
• To discuss the expanding use of MMF in high-risk renal transplant recipients and non-transplant autoimmune diseases.

Main Methods:

• Review of pharmacological properties of MMF.
• Analysis of prospective clinical studies involving MMF.
• Summary of long-term outcomes data from national transplant registries.
• Discussion of MMF's application in specific patient populations and conditions.

Main Results:

• MMF is widely adopted in solid organ transplantation.
• Data on long-term outcomes in kidney and liver transplantation are available.
• MMF is increasingly used in high-risk renal transplant recipients.
• MMF also finds application in autoimmune diseases.

Conclusions:

• The established benefits of MMF in transplantation require re-evaluation.
• Future assessments must consider concurrent use of MMF with other agents like tacrolimus, sirolimus, and newer drugs.
• The evolving landscape of immunosuppression necessitates ongoing study of MMF's role.